Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Lotus Pharmaceuticals, Inc. (LTUS) Receives Phase I Approval for Asthma Drug

Lotus Pharmaceuticals, Inc. reported that the company has received approval from the regulatory authorities in China to begin Phase I clinical trials for one of its drug candidates – R-Bambuterol Hydrochloride, which is used to treat Asthma

Lotus Pharmaceuticals, Inc. said that the Phase I trials would include studying the tolerance of the drug in humans, and pharmacokinetics, which is the study of what the body does to the drug after dosage.

Lotus Pharmaceuticals, Inc. said that research conducted by a third party indicated that the Asthma market in China is approximately $300 million annually, and as many as 40 million suffer from the condition.

The Beijing Zenith International Medical Science and Technology Development Company Limited will conduct the Phase I clinical trials. Lotus Pharmaceuticals, Inc. said that R-Bambuterol Hydrochloride is a Class I drug, which gives Lotus Pharmaceuticals, Inc. patent protection for 22 years.

Lotus Pharmaceuticals, Inc. does business through Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, two controlled entities. The company is also working on drugs to treat cerebro-cardiovascular diseases and diabetes.

For more information on the company, go to

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *